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Raghu KalluriMD Anderson Cancer Center, Texas

Sanger's initial effort to sequence the human genome evidenced that for the accurate, cost-effective, and high-throughput sequencing of genetic material, we would need dedicated teams of chemists, engineers, mathematicians, and biologists to innovate at the highest level. Such coordinated effort led to the refinement of bulk sequencing to single-cell resolution. While single-cell studies began with DNA analysis, they rapidly expanded to RNA (scRNA-seq), epigenome, and proteins (CyTOF). As a result, cancer cells have been defined and stratified at the finest resolution, with insights into clonal evolution and accumulation of somatic mutations. scRNA-seq has revolutionized our appreciation of tumor composition and complexity, aiding in establishing cellular clusters and arranging them in hierarchies. Big-data computing has dramatically enhanced our appreciation of cellular heterogeneity within tumors and identified new cellular variants. However, solid tumors have been challenging to study due to the differential impact of tissue dissociation on cell viability, resulting in relative cellular ratios that are not always reflective of the actual tumor content. This is further complicated by the difficulty in determining whether expression "dropout" is due to technical reasons or is a biologically relevant absence of expression. Parallel scRNA-seq and CyTOF analysis has shown that certain proteins are identified despite lack of mRNA detection. Such discrepancies caution against jumping to "function" assignments based on scRNA-seq. Nevertheless, such challenges keep motivating teamwork and innovation, further exploiting techniques such as RNA expression and protein (REAP)-seq to provide more in-depth insights into molecular and functional architecture of tumors.
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Adam J. MeadMRC Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom

Cancer cell heterogeneity is a major driver of therapy resistance and disease progression in blood cancers. While this heterogeneity is partly driven by well-documented somatic genetic mutation, it also occurs on many other levels, including presence of cancer stem cells, infiltrating immune cells, epigenetics and microenvironmental factors, and cell cycle, to name a few. Single-cell multi-omic techniques are ideally placed to unravel this heterogeneity and are poised as a powerful tool for precision oncology. The ultimate aim will be to refine approaches for diagnosis and risk stratification, monitoring of measurable residual disease, understanding of therapy response and resistance mechanisms, biomarker discovery, and rational design of novel therapeutics.

However, while technical aspects of single-cell analyses have advanced at a remarkable pace, with computational tools following close behind, considerable challenges remain. Moving single-cell genomics closer to clinical application will require analysis of patient cohorts at scale with integration of clinical and laboratory data. Blood cancers have the advantage of relative ease of serial sampling. Important practical considerations include standardization of approaches for serial sample banking pre- and post-therapy and implementation of good clinical laboratory practice (GCLP), which is essential for clinical research. Integration of single-cell-analysis-based novel exploratory endpoints into prospective clinical trials of novel therapies will be an important first step in the application of this exciting new technology in blood cancers toward precision oncology, drug discovery, and direct patient benefit.
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Marina Pasca di MaglianoDepartment of Surgery, University of Michigan, Michigan

Pancreatic cancer, like other tumors, is formed by more than cancer cells. Vasculature elements, nerves, fibroblasts, and immune cells are abundant, and are important to cancer progression and response to therapy. But how many types of cells are present within a tumor, and how do they interact with each other? How heterogeneous are those non-tumor cell types in the primary tumor versus in metastatic sites, or in tumors of different patients? Single-cell mRNA sequencing gives us the possibility of interrogating the tumor microenvironment to identify rare cell populations, map signal transduction, and predict cellular interactions. For my laboratory, single-cell sequencing has both contributed to mechanistic understanding of the interactions within the cancer microenvironment and served as a hypothesis-generating tool, leading the way to future functional studies.

Entering single-cell sequencing required building a team of collaborators working closely together with diverse expertise, from the biology of cancer to the intricacies of data analysis and bioinformatics. Single-cell sequencing has also changed the physical nature of my laboratory and our equipment needs. Initially, this change led to the challenge to keep up with computing power and data storage. Now, as the University of Michigan laboratories are in shutdown mode due to the COVID-19 outbreak, our bioinformatics projects can continue remotely: diversity in our scientific endeavor is providing resilience. At the same time, as technology becomes more sophisticated and more expensive, it creates an ever-widening gap between laboratories that can afford it and those that can't. Sharing data and open access knowledge has never been more important.
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Mariella FilbinDana-Farber Cancer Institute, Massachusetts

To a first approximation, solid tumors in adults are an age-related outcome of exposure to environmental insults. How and why do children get cancer? The question is especially compelling for pediatric brain cancers, given the brain's isolation from many environmental toxins. Analysis of pediatric brain cancers by single-cell RNA sequencing (scRNA-seq) has highlighted developmental origins of pediatric brain tumors and changed the way we might treat them.

For example, in diffuse intrinsic pontine glioma (DIPG), a uniformly fatal high-grade glioma of childhood, scRNA-seq of patient-derived materials shows that DIPGs are mostly composed of replicating cells that resemble glial progenitors. However, a subset of tumor cells exit the cell cycle and partially differentiate toward oligodendrocyte- and astrocyte-like cells, thereby losing their tumorigenicity. In other studies, scRNA-seq unmasked developmental origins of medulloblastoma and ependymoma---two other aggressive pediatric brain tumors. Again, scRNA-seq showed that (1) that tumor growth is driven by a subpopulation of stem-like cells and (2) some of these stem-like cells escape the replication-competent state and express early markers of brain development.

Can the latent potential of pediatric brain cancers be manipulated and amplified toward a therapeutic end? As a pediatric neuro-oncologist, I am hoping to see practical overtones of scRNA-seq in the clinic within the next few years. Our pediatric patients cannot wait.
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Peter CarmelietLeuven Cancer Institute, Belgium; and Sun Yat-Sen University, China

Endothelial cells (ECs), lining blood vessels, are highly plastic. ECs in arteries, capillaries, and veins, as well as in different tissues and even within one vessel type, exhibit distinct gene expression signatures. Single-cell RNA sequencing (scRNaseq) of tens of thousands of tumor ECs (TECs) revealed multiple novel phenotypes and insights. For instance, only few angiogenic TECs (target cells of anti-angiogenic therapy \[AAT\]) were identified in human lung tumors, possibly contributing to the resistance against AATs. Also, more TECs seemed to be involved in cancer immunity than anticipated, suggesting that tuning, rather than pruning, TEC phenotypes might offer novel AAT opportunities. Outstanding is if similar TEC phenotypes are present in other cancer types, which would address if future AATs should be tissue specific. Another challenge for future scRNaseq studies is no longer to generate only descriptive atlas-like lists of marker genes but also to develop new approaches to prioritize therapeutic targets among the thousands of markers. This could, for instance, be achieved by defining top-ranking markers that are congruent in TECs across tumor types, tissues, and species, hypothesizing that conserved markers are likely to be biologically relevant. This may require an integrated analysis of orthogonal multi-omics and meta-analysis data. Identifying spatial scRNaseq-validated interactomes between TECs and other tumor cell types, and defining epigenetic regulation of single TEC transcriptomes, also promises to yield new insights.
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Ido AmitWeizmann Institute, Israel

Despite the significant improvement in development of targeted small molecules and antibody-based therapeutics, we currently lack thorough understanding of the cells and pathways affected by these agents. Single-cell technologies have already trailblazed characterization of the cellular and molecular complexity of the tumor microenvironment (TME). I believe that this is only the beginning of the translational single-cell genomic era and that emerging single-cell technologies will continue to serve as an engine for more effective target identification and drug development.

Detailed single-cell maps of the immune, tumor, and stromal cell compositions in large patient cohorts serve to identify cell states and molecular pathways of high therapeutic potential and drug-resistance mechanisms in each disease. This approach can also identify patients most likely to benefit from specific treatments. At the pre-clinical stage, comparative single-cell analysis may reveal similarities and dissimilarities between human and model animal TMEs, enabling data-driven selection of the most effective tumor model. Later, single-cell profiling of responding versus non-responding cells and pathways may reveal potential biomarkers for companion diagnostic tests. Finally, the molecular resolution of single-cell profiling will enable us to delineate synergistic, additive, or antagonistic activities and devise improved combination immunotherapy. These initial applications of single-cell genomics in the drug development pipeline are signs of an emerging revolution in the battle against cancer.
